Companies: 10,795·Total market cap: $144.5T
CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc.

CTMXNASDAQHealthcare● Active
$3.00
$-0.18(-5.66%)
Market Cap$482470587
P/E Ratio
52W High$8.21
52W Low$1.72
Overview

CytomX Therapeutics, Inc. (CTMX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · CTMX · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-0.36ctmx eps ttm · ctmx earnings per shareEarnings history
PE Ratio (TTM)ctmx pe ratio ttm · ctmx price to earningsPE Ratio deep dive
Revenue (TTM)$35.5Mctmx revenue ttm · ctmx annual revenueFull revenue history
Dividend YieldNo Dividenddoes ctmx pay dividends · ctmx dividend yieldDividend history
Shares Outstanding137.9Mctmx shares outstanding · ctmx floatShares outstanding history
Next EarningsAug 6, 2026Est.ctmx earnings date · ctmx next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$76.2M▼ 44.82% YoY
202320242025
cytomx therapeutics, inc. revenue · ctmx revenue 2025
FY 2025Net Income-$17.4M▼ 154.50% YoY
202320242025
cytomx therapeutics, inc. net income · ctmx profit 2025
FY 2025EPS$-0.15▼ 139.47% YoY
202320242025
ctmx eps · cytomx therapeutics, inc. earnings per share 2025
TTM:Revenue: $35.5MNet Income: -$59.1MEPS: $-0.36View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy21 analystsis ctmx a buy · ctmx analyst rating
Strong Buy
0
Buy
17
Hold
4
Sell
0
Strong Sell
0
12-Month Price Target
$6.00Low
$3.00Current
$10.71Avg Target257.00% upside
$16.00High
ctmx price target · ctmx 12 month forecast

Total: 21 · Buy rate: 81.0%

The CTMX analyst consensus is Buy, based on ratings from 21 Wall Street analysts over the past 3 months. The average 12-month price target is $10.71, representing +257.00% upside from the current price of $3.00.

Stock Performance

Full History
1D-5.66%
1W-6.83%
1M-24.62%
3M-35.90%
YTD-29.58%
1Y+13.64%
5Y-57.02%

About CytomX Therapeutics, Inc.

CEOSean A. McCarthy
IPO DateOct 8, 2015
Employees119
CountryUS
Websitecytomx.com

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the tr…

what is cytomx therapeutics, inc. · ctmx stock overview · cytomx therapeutics, inc. company profile · who is cytomx therapeutics, inc. ceo · ctmx NASDAQ · cytomx therapeutics, inc. headquarters · cytomx therapeutics, inc. business segments

About Stock Overview & Key Data

CytomX Therapeutics, Inc. (CTMX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 8, 2015. As of the latest trading session, CTMX stock price is $3.00, with a market capitalization of $482.5M. The stock has returned +13.64% over the past 12 months and -29.58% year-to-date.

According to 21 Wall Street analysts, the consensus rating for CytomX Therapeutics, Inc. stock is Buy, with an average 12-month price target of $10.71. In fiscal year 2025, CytomX Therapeutics, Inc. reported revenue of $76.2M and net income of -$17.4M. For detailed data — including CytomX Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, CytomX Therapeutics, Inc. (CTMX) stock price is $3.00. The stock is traded on NASDAQ under the ticker symbol CTMX. The 52-week range is $1.72 – $8.21.

CTMX stock priceCTMX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice